UDMTek designated disclosure-rule violator over contract termination reversal, hit with 3 penalty points
Bitget2026/10/08 10:46UDMTek was designated a disclosure-rule violator for reversing a prior filing tied to a terminated single-sales supply contract. The breach relates to an original disclosure dated June 10, 2026, with the reversal disclosed on July 20, 2026. The Korea Exchange set the designation date for Oct. 12, 2026, following an Aug. 19, 2026, advance notice. A 3.0 penalty-point sanction was imposed, bringing the company’s trailing 12-month total to 3.0 points. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. UDMTek Co. Ltd. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261008900934), on October 08, 2026, and is solely responsible for the information contained therein.
- UDMTek was designated a disclosure-rule violator for reversing a prior filing tied to a terminated single-sales supply contract.
- The breach relates to an original disclosure dated June 10, 2026, with the reversal disclosed on July 20, 2026.
- The Korea Exchange set the designation date for Oct. 12, 2026, following an Aug. 19, 2026, advance notice.
- A 3.0 penalty-point sanction was imposed, bringing the company’s trailing 12-month total to 3.0 points.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Canaccord Genuity: Lowers Oklo's target price to $66
"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.
Dental treatment company vVardis has announced the terms for its $214 million US IPO.
Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss
Novo Nordisk reports that some patients treated with Wegovy have shown improvements in liver conditions.
Crypto prices
More
